Ingrid Markovic, PhD U.S. FDA

Ingrid Markovic, PhD

Ingrid Markovic, PhD U.S. FDA Senior Science Advisor, Office of the Center Director, ORO, CBER

Ingrid Markovic, Ph.D. is Senior Science Advisor in the FDA/CBER Immediate Office of the Center Director, where she is responsible for providing leadership, strategic roadmap and guidance for development, implementation and integration of CMC policies for biological and biotechnological products. In this role, she forms key strategic partnerships ensuring consistent interpretation and application of CMC policies across, and between, Centers.

In the international arena, Ingrid serves as CBER ICH Quality Lead. She is/was FDA topic co-lead for Q12, QDG, and, most recently, M4Q. She had an opportunity to briefly serve as ICH Q3E Rapporteur. Prior to her current role, Ingrid worked in the industry sector leading US & EU CMC Reg Policy efforts focusing on Technological Innovation and Cell & Gene Therapies. She collaborated with Trades Associations supporting continual improvement and innovation in the Biopharmaceutical sector.